Table 4.

Differences in mean Hb in Europe, Japan, and United States black patients compared with United States nonblack patients by calendar time and model used to adjust for covariates

Month/Yeara	Unadjusted	95% CI	Model 1b	95% CI	Model 2c	95% CI	Model 3d	95% CI
Europee
08/2010	−0.10	−0.23 to 0.03	−0.08	−0.21 to 0.05	−0.08	−0.23 to 0.08	−0.07	−0.22 to 0.09
12/2011	0.55	0.39 to 0.70	0.60	0.45 to 0.75	0.57	0.39 to 0.75	0.58	0.40 to 0.76
04/2013	0.53	0.41 to 0.65	0.58	0.44 to 0.72	0.56	0.38 to 0.74	0.56	0.38 to 0.74
Japan
08/2010	−1.01	−1.20 to −0.82	−0.94	−1.14 to −0.74	−0.97	−1.19 to −0.75	−0.93	−1.15 to −0.72
12/2011	−0.20	−0.35 to −0.05	−0.15	−0.32 to 0.02	−0.17	−0.38 to 0.03	−0.14	−0.34 to 0.06
04/2013	−0.05	−0.19 to 0.09	−0.01	−0.17 to 0.14	−0.04	−0.25 to 0.16	−0.01	−0.21 to 0.19
United States black
08/2010	0.11	0.01 to 0.21	0.14	0.04 to 0.24	0.13	0.04 to 0.23	0.13	0.04 to 0.22
12/2011	−0.06	−0.23 to 0.10	−0.05	−0.21 to 0.12	−0.03	−0.19 to 0.13	−0.03	−0.19 to 0.12
04/2013	−0.03	−0.13 to 0.06	−0.01	−0.09 to 0.08	0.00	−0.09 to 0.08	−0.01	−0.09 to 0.07

^aFacility sample transitioned from the DOPPS 4 to the DOPPS 5 during January to April of 2012.

^bModel 1 includes age, years on dialysis, black race (United States only), sex, catheter use, diabetes, history of gastrointestinal bleeding, creatinine, and most recent albumin level in the prior 3 months.

^cModel 2 includes model 1 adjustments plus iv iron use in the prior 3 months (yes or no), most recent transferrin saturation and ferritin levels in the prior 3 months, and facility–reported upper Hb target.

^dModel 3 includes model 2 adjustments plus predialysis body weight.

^eEurope includes the DOPPS facility samples in Germany, Italy, Spain, and the United Kingdom.